91ÑÇɫ

About IP Osgoode

IP Osgoode is an independent voice that explores legal governance issues at the intersection of intellectual property (IP) and technology. The program’s researchers, collaborators, and students actively engage in some of the most important and cutting-edge IP law and technology related research and policy discussions of today.


Latest from IPilogue

Commentary and analysis on the latest developments in intellectual property, technology and privacy, featuring curated contributions from students, scholars, and experts within the Osgoode community.

Innovation or Bust: Legal Avenues not enough to save Record Labels

Nov 13, 2007 1 min read
dummy-img

Warner Music Group’s recent announcement about wider losses in the third quarter, due to an increasing trend of consumers switching to digital downloads, highlights the changing nature of the music industry.   Even as Warner posted higher overall losses due largely to the decline in CD sales, its digital revenues were up 29% from the […]

Thailand vs. Pharma-Giants: Challenging the Justification for IP

Nov 13, 2007 2 min read
dummy-img

In an attempt to control the HIV/AIDS epidemic in Thailand, the Thai government decided to bypass the patents on anti-retroviral drugs (ARVs) by issuing compulsory licenses to manufacture generic copies of these drugs. The result of this gutsy move is affordable, locally-made alternatives that are dispensed to patients for free via the government's universal healthcare […]

French student arrested for posting non-authorized copies of Harry Potter

Nov 13, 2007 2 min read
dummy-img

When a French teen becomes the target of police and is subjected to their interrogation while spending a night behind bars, one would imagine that perhaps the teen had committed a serious criminal act. Not so in this case. In July 2007, just a few days after the final Harry Potter novel was released in […]

Novartis challenges Indian IP law

Nov 13, 2007 2 min read
dummy-img

A Swiss pharmaceutical company, Novartis, sought to have the January 2006 decision to reject its patent application for the cancer drug imatinib mesylate (Gleevec) reversed by the Chennai High Court in India. Gleevec is used in the treatment of Leukemia. Novartis sells Gleevec at $2500 per patient per month in India; generic versions cost $175 […]

Micropayments - Are they good or bad for IP?

Nov 13, 2007 1 min read
dummy-img

On August 27, 2007, the International Herald Tribune published an article by Dan Mitchell titled “Micropayments arrive on the Web.” This piece examined the evolution and reemergence of the use of small user fees, known as micropayments, in exchange for content on the internet. After reading Mitchell’s article, the main question that comes to mind […]

Synthetic Life Forms – The New Patent Frontier

Nov 13, 2007 1 min read
dummy-img

In May of 2007 scientists at J. Craig Venter Institute filed a U.S. patent application on the world's first synthetic living organism (U.S. Patent application number 20070122826). The patent application claims include a set of essential genes required to provide the bare essentials of life as well as a "free-living organism that can grow and […]

Editor in Chief: Prof. Carys Craig (ccraig@osgoode.yorku.ca)
Submission inquiries: iposgoode@osgoode.yorku.ca